Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) had its target price decreased by Barclays from $62.00 to $60.00 in a report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.
Other equities research analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group increased their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $61.33.
Get Our Latest Research Report on TARS
Tarsus Pharmaceuticals Trading Up 2.1 %
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Research analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $25,000. GF Fund Management CO. LTD. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $44,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $53,000. FMR LLC raised its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. Institutional investors own 90.01% of the company’s stock.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Recommended Stories
- Five stocks we like better than Tarsus Pharmaceuticals
- How is Compound Interest Calculated?
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 5 Best Gold ETFs for March to Curb Recession Fears
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.